Agilent: Back To The Lab - [Business Breakdowns, EP.223]

Episode Summary

Executive Summary: The episode breaks down Agilent as a specialized, high-quality life sciences tools business with deep roots in HP. It earns recurring revenue from instruments, consumables, service, and software, benefits from entrenched customer relationships and regulatory stickiness, and is expanding into oligonucleotide production. Despite cyclicality in pharma and China, the business has strong margins, cash flow, and long-term growth potential.

Main Topics: What Agilent Does (Priority: 5/5): Agilent sells lab instruments, services, consumables, and software that identify and quantify molecules in samples for pharma, academia, chemicals, food, and environmental testing. History and Spinout from HP (Priority: 5/5): Agilent originated from Hewlett-Packard’s testing business, later spun off in 1999, and then refocused through divestitures and the 2014 Keysight spin into a pure analytical/life sciences tools company. Razor-and-Razorblade Model (Priority: 5/5): The core business is one-third instruments and two-thirds recurring consumables/service/software, creating durable customer lock-in and recurring revenue tied to installed base and regulated workflows. Competition and Market Position (Priority: 4/5): Agilent competes mainly with Waters and Thermo Fisher, but holds leading positions in key niches like gas chromatography and strong share in liquid chromatography and spectroscopy. Growth, Cyclicality, and End Markets (Priority: 4/5): Revenue is diversified across pharma, academia/government, chemicals, and food/environmental testing, but still exposed to pharma capex cycles and China demand swings. New Growth Area: NASD/Oligonucleotides (Priority: 4/5): Agilent expanded into nucleic acid solutions, producing oligos used in RNA-based drugs and vaccines, becoming a leader in a fast-growing adjacent CDMO-like niche. Capital Allocation and Valuation (Priority: 3/5): The company has a cautious balance sheet, uses small bolt-on M&A selectively, and appears reasonably valued on free cash flow yield and earnings multiples.

Key Arguments: Agilent is a leading lab tools company whose value comes from selling both the instrument and the recurring ecosystem around it. Its customer base is broad, but pharma is the largest end market, making the company both diversified and exposed to pharma capex cycles. Chromatography instruments are mission-critical and sticky because they are often embedded in regulated processes and approvals. Service quality is a major competitive moat, supported by 4,000 direct technicians and a dense service network. Agilent’s market shares are generally stable because switching costs are high and customers rarely replace entire labs. The company’s recurring service/consumables attach rate is rising, which should support margin expansion and earnings growth. The oligonucleotide business is a meaningful adjacent growth platform, backed by real capital investment and structural demand in RNA-based therapeutics. Valuation is attractive when assessed through free cash flow yield, especially given stable cash conversion and high-single-digit earnings growth potential.

Data Points: Market cap: $30 billion - Approximate market capitalization at the time of recording Revenue: $6.5 billion - Current annual revenue referenced for Agilent TAM: $160 billion - Agilent’s published total addressable market Countries served: 110 - Geographic footprint described in the discussion Labs served: 285,000 - Estimated number of labs using Agilent products globally Pharma sales mix: ~33% - Largest end market for Agilent Academia/government sales mix: ~10% - Smaller end market exposure Chemicals/advanced materials sales mix: ~20% - Includes battery testing and semiconductor production applications Food/environmental testing sales mix: ~20% - Includes contaminants testing in water and food Instrument vs recurring mix: ~1/3 instruments, ~2/3 consumables/service/software - Core razor-and-razorblade business model Typical chromatography instrument price: ~$100,000 - Approximate selling price per instrument Instrument useful life: 6–10 years - Expected economic life of chromatography instruments Recurring spend per instrument over life: ~$100,000 - Ongoing consumables and service spend over useful life Service attach rate: Low 30s% - Percentage of installed base with active service contracts, up from high 20s over five years Service attach rate peer benchmark: 50s% - Waters’ service contract attach rate Operating margin, life sciences instrument sales: ~20% - Margin profile for instruments sold into life sciences Operating margin, applied markets instrument sales: ~24% - Higher-margin instrument sales in applied markets Operating margin, consumables and servicing: ~34% - Highest-margin recurring segment Free cash flow: ~$1.4 billion - Annual free cash flow generated by the company Free cash flow conversion: ~90% of adjusted net income - Stable recent cash conversion Organic sales growth: ~5% CAGR since 2015 - Average post-Keysight spin organic revenue growth Reported sales growth: ~6% CAGR since 2015 - Includes bolt-on M&A contribution EPS growth: ~13% CAGR over nine years - Reflects margin expansion and capital allocation China sales mix: ~18% - Share of group sales coming from China NIH-related funding exposure: ~1% of sales - Limited dependence on U.S. government funding Service technicians: 4,000 - Directly employed service workforce Technician qualifications: 75% chemistry/biochemistry degrees; 25% master’s or PhD - Illustrates technical depth of service organization On-site service calls: 2,500 per day - Daily service activity handled by Agilent NASD revenue: $300+ million - Internal oligonucleotide business revenue BioVectra acquisition value: ~$1 billion - Acquired business supporting NASD capabilities Combined NASD/BioVectra revenue: ~$470 million - Total revenue from the nucleic acid solutions segment NASD share of sales: ~7% - Approximate share of total Agilent revenue Initial NASD investment: $185 million - 2018 capex decision to expand production Further NASD expansion: $725 million - 2023 groundbreaking for additional facility expansion PFAS market size: $400 million - Fast-growing testing market cited as a new opportunity PFAS growth rate: ~20% per year - Growth rate of the PFAS testing market Balance sheet leverage: ~1.0x net debt/EBITDA - Described as cautious balance sheet management Free cash flow yield: Above 4% - Valuation referenced as near 10-year highs P/E multiple: Just under 20x - Alternative valuation framing used by the guest

Pivotal Quotes: "Agilent is a leading provider of instruments, services, and consumables for labs." — Mark DeVos: Simple definition of the company’s core business "If I was to tell you at the pub about a business that services lab instruments, you might be forgiven for telling me to move on. Actually, this is a fantastic business." — Mark DeVos: Lesson on not underestimating a seemingly boring but high-quality business "It’s a classic density business whereby you’re in a city, you’ve got five technicians that operate in that city. Take on 5% more business. You don’t need an extra person." — Mark DeVos: Explanation of why the service segment scales efficiently

Implications: Agilent shows how niche tools businesses can create durable compounding through installed-base stickiness, recurring revenue, and regulated end markets. Investors should watch service attach rates, PFAS/testing regulation, pharma cycles, and the oligo expansion as key drivers.